Patent · US Active

Selective androgen receptor degrader (SARD) ligands and methods of use thereof

US10597354B2 · kind B2 · utility

7Cited by

15References

20Claims

0Family size

Assignees

University of Tennessee Research Foundation · US
Oncternal Therapeutics, Inc. · US

Inventors

Ramesh Narayanan · Cordova, US
Duane D. Miller · Germantown, US
Thamarai Ponnusamy · Memphis, US
Dong-Jin Hwang · Arlington, US
Charles B. Duke · Memphis, US
Christopher C. Coss · Upper Arlington, US
Amanda Jones · Gaylord, US
James T. Dalton · Columbus, US

Key dates

Filing date	Oct 5, 2018
Grant date	Mar 24, 2020
Priority date	—
Expiry date	Oct 5, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention provides novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other 5 hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.